Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

about

Correction of the Definition of MGUS.

P2860

Q55025910-2BBC51EB-41B2-4EE1-BC3B-D5E5372D1A7B

P2860

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

Item

http://www.wikidata.org/entity/Q47134329

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

@en

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

@nl

type

Item

label

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

@en

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

@nl

prefLabel

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

@en

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

@nl

P1476

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

@en

P2093

Alexander Grunenberg

http://www.w3.org/2001/XMLSchema#string

Christian Buske

http://www.w3.org/2001/XMLSchema#string

P2860

Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Cold agglutinin disease

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

P304

745-751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3238/ARZTEBL.2017.0745

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29169431

http://www.w3.org/2001/XMLSchema#string

P932

5719232

http://www.w3.org/2001/XMLSchema#string

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

about

P2860

P2860

Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932